Literature DB >> 30123547

Personalized treatment of malignant mesothelioma-dream or reality?

Anja C Roden1.   

Abstract

Entities:  

Year:  2018        PMID： 30123547      PMCID： PMC6072927          DOI： 10.21037/jtd.2018.06.67

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

2.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

3.  Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

Authors:  Guangwu Guo; Juliann Chmielecki; Chandra Goparaju; Adriana Heguy; Igor Dolgalev; Michele Carbone; Sara Seepo; Matthew Meyerson; Harvey I Pass
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701

4.  Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.

Authors:  Raghavendra Pillappa; Joseph J Maleszewski; William R Sukov; Patrick P Bedroske; Patricia T Greipp; Jennifer M Boland; Eunhee S Yi; Tobias Peikert; Marie Christine Aubry; Anja C Roden
Journal:  Am J Surg Pathol       Date:  2018-02       Impact factor: 6.394

5.  BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.

Authors:  Luisella Righi; Eleonora Duregon; Simona Vatrano; Stefania Izzo; Jessica Giorcelli; Milena Rondón-Lagos; Valeria Ascoli; Enrico Ruffini; Laura Ventura; Marco Volante; Mauro Papotti; Giorgio Vittorio Scagliotti
Journal:  J Thorac Oncol       Date:  2016-07-13       Impact factor: 15.609

6.  Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.

Authors:  Lucian R Chirieac; Justine A Barletta; Beow Y Yeap; William G Richards; Tamara Tilleman; Raphael Bueno; Elizabeth H Baldini; John Godleski; David J Sugarbaker
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

7.  Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.

Authors:  Yin P Hung; Fei Dong; Jaclyn C Watkins; Valentina Nardi; Raphael Bueno; Paola Dal Cin; John J Godleski; Christopher P Crum; Lucian R Chirieac
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

8.  In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Authors:  Peter W Szlosarek; Astero Klabatsa; Arben Pallaska; Michael Sheaff; Paul Smith; Tim Crook; Matthew J Grimshaw; Jeremy P Steele; Robin M Rudd; Frances R Balkwill; Dean A Fennell
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

9.  Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Authors:  Peter W Szlosarek; Jeremy P Steele; Luke Nolan; David Gilligan; Paul Taylor; James Spicer; Michael Lind; Sankhasuvra Mitra; Jonathan Shamash; Melissa M Phillips; Phuong Luong; Sarah Payne; Paul Hillman; Stephen Ellis; Teresa Szyszko; Gairin Dancey; Lee Butcher; Stephan Beck; Norbert E Avril; Jim Thomson; Amanda Johnston; Marianne Tomsa; Cheryl Lawrence; Peter Schmid; Timothy Crook; Bor-Wen Wu; John S Bomalaski; Nicholas Lemoine; Michael T Sheaff; Robin M Rudd; Dean Fennell; Allan Hackshaw
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

10.  Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

Authors:  Krishna Kalyan Kolluri; Constantine Alifrangis; Neelam Kumar; Yuki Ishii; Stacey Price; Magali Michaut; Steven Williams; Syd Barthorpe; Howard Lightfoot; Sara Busacca; Annabel Sharkey; Zhenqiang Yuan; Elizabeth K Sage; Sabarinath Vallath; John Le Quesne; David A Tice; Doraid Alrifai; Sylvia von Karstedt; Antonella Montinaro; Naomi Guppy; David A Waller; Apostolos Nakas; Robert Good; Alan Holmes; Henning Walczak; Dean A Fennell; Mathew Garnett; Francesco Iorio; Lodewyk Wessels; Ultan McDermott; Samuel M Janes
Journal:  Elife       Date:  2018-01-18       Impact factor: 8.140
View more
  1 in total

1.  Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.

Authors:  Claudio Pulito; Etleva Korita; Andrea Sacconi; Mariacristina Valerio; Luca Casadei; Federica Lo Sardo; Federica Mori; Maria Ferraiuolo; Giuseppe Grasso; Anna Maidecchi; Jacopo Lucci; Marius Sudol; Paola Muti; Giovanni Blandino; Sabrina Strano
Journal:  J Exp Clin Cancer Res       Date:  2019-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.